Kaweah Delta Health Care District
Kaweah Delta Health Care District was paid $83.04M by Medicaid between Jan 2018 and Dec 2024, across 546 billing codes. Its largest line is 0450, Emergency room services — 25% of everything it billed.
33Billing provider infoKAWEAH DELTA HEALTH CARE DISTRICT
VISALIA, CA 93291
VISALIA, CA 93291
33aNPI1588663769assigned 07/19/2005
33bProvider typeCase Manager/Care Coordinator
28Total paid$83.04M
24GClaims3,007,605
24DCodes billed546
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Case Manager/Care Coordinator providers in California
Rank by total paid#18 of 435
Median peer was paid$2.89M
This provider vs. median29×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official TUPPER, MALINDA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 358,040 | $8.95M | |
| 2019 | 345,492 | $8.37M | |
| 2020 | 360,550 | $9.49M | |
| 2021 | 445,771 | $11.92M | |
| 2022 | 493,925 | $13.61M | |
| 2023 | 559,223 | $17.11M | |
| 2024incomplete | 444,604 | $13.59M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 25% | 165,352 | 143,334 | $20.60M |
| 80053 | Comprehensive metabolic panel | 5.2% | 131,381 | 118,318 | $4.28M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.9% | 94,215 | 87,382 | $4.11M |
| 99199 | Unlisted special service, procedure or report | 3.6% | 58,929 | 48,307 | $3.00M |
| G9012 | Other specified case management service not elsewhere classified | 3.3% | 24,667 | 9,288 | $2.71M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.5% | 67,862 | 61,957 | $2.10M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 71,793 | 16,707 | $1.72M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 17,280 | 16,784 | $1.63M |
| 87428 | 1.7% | 33,482 | 31,779 | $1.45M | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.7% | 29,545 | 28,425 | $1.41M |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.5% | 26,970 | 22,504 | $1.26M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 9,627 | 9,328 | $984K |
534 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 14,459 | $895K |
| 0160 | 1.0% | 14,289 | $850K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 68,099 | $778K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 156,354 | $773K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 48,351 | $767K |
| 97139 | <1% | 42,519 | $738K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 24,962 | $732K |
| H0043 | Supported housing, per diem | <1% | 5,355 | $649K |
| 97750 | <1% | 14,068 | $642K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 14,862 | $625K |
| 97010 | <1% | 13,987 | $594K | |
| 0760 | <1% | 18,017 | $593K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 47,881 | $559K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 17,939 | $558K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 724 | $509K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 3,889 | $501K |
| 95811 | <1% | 2,585 | $492K | |
| J3490 | Unclassified drugs | <1% | 12,646 | $468K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 25,228 | $458K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,852 | $428K |
| 93325 | <1% | 4,403 | $423K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 31,117 | $415K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,533 | $407K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 899 | $405K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,409 | $381K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 13,440 | $377K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 13,820 | $366K |
| 0360 | <1% | 2,684 | $366K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 12,037 | $360K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 14,233 | $332K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,944 | $325K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 25,453 | $324K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,861 | $312K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 5,887 | $308K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,662 | $302K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 18,139 | $300K |
| 80061 | Lipid panel | <1% | 22,642 | $298K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 8,596 | $297K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 11,137 | $294K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,634 | $290K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 6,397 | $288K |
| 84484 | <1% | 43,849 | $287K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 16,045 | $287K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 11,132 | $282K |
| 87634 | <1% | 7,868 | $265K | |
| 71045 | Radiologic examination, chest; single view | <1% | 22,481 | $263K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 26,621 | $254K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 22,247 | $254K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,928 | $254K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 18,791 | $252K |
| 36415 | Collection of venous blood by venipuncture | <1% | 68,083 | $244K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 11,993 | $241K |
| 93320 | <1% | 3,878 | $235K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 5,936 | $217K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 1,138 | $208K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 6,244 | $195K |
| 99285 | Emergency room visit (most serious) | <1% | 2,502 | $195K |
| 81001 | <1% | 63,194 | $194K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 13,431 | $193K |
| 82803 | <1% | 20,903 | $193K | |
| Z7502 | <1% | 5,069 | $192K | |
| 0270 | <1% | 3,802 | $189K | |
| 76770 | <1% | 4,135 | $183K | |
| 76801 | <1% | 6,322 | $183K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,765 | $172K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,812 | $172K |
| 0720 | <1% | 3,527 | $167K | |
| 76830 | Ultrasound, transvaginal | <1% | 4,858 | $166K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 5,407 | $166K |
| 99284 | Emergency room visit (serious) | <1% | 2,184 | $164K |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 1,510 | $163K |
| 70496 | <1% | 1,680 | $160K | |
| 82330 | <1% | 19,817 | $159K | |
| 87481 | <1% | 5,233 | $158K | |
| G9008 | Coordinated care fee, physician coordinated care oversight services | <1% | 1,343 | $157K |
| 81025 | <1% | 18,338 | $155K | |
| 97799 | <1% | 9,621 | $154K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 1,964 | $151K |
| 83605 | <1% | 24,948 | $150K | |
| 73130 | <1% | 6,981 | $148K | |
| 93971 | <1% | 3,171 | $147K | |
| 83880 | <1% | 11,733 | $145K | |
| 0761 | <1% | 4,081 | $141K | |
| 97165 | <1% | 3,485 | $140K | |
| 73630 | <1% | 6,640 | $137K | |
| 73610 | <1% | 5,883 | $136K | |
| 83690 | <1% | 38,030 | $133K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,099 | $133K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 814 | $131K |
| 93970 | <1% | 1,404 | $130K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 2,513 | $129K |
| 83735 | <1% | 25,475 | $129K | |
| 76641 | <1% | 2,393 | $128K | |
| 93017 | <1% | 3,530 | $123K | |
| 80074 | <1% | 2,788 | $123K | |
| 73030 | <1% | 5,652 | $122K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 25,425 | $120K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 10,008 | $120K |
| 80076 | <1% | 5,077 | $118K | |
| 99283 | Emergency room visit (moderate) | <1% | 1,748 | $117K |
| 72141 | <1% | 556 | $115K | |
| 70498 | <1% | 1,985 | $114K | |
| 82947 | <1% | 31,918 | $113K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,785 | $107K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 5,517 | $106K |
| 72110 | <1% | 2,449 | $102K | |
| 86850 | <1% | 15,023 | $102K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 4,931 | $100K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 6,331 | $99K |
| 84439 | <1% | 13,089 | $94K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,169 | $93K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,897 | $92K |
| 82375 | <1% | 11,343 | $91K | |
| 86480 | <1% | 1,810 | $90K | |
| 70486 | <1% | 1,220 | $90K | |
| 96379 | <1% | 4,310 | $89K | |
| 59025 | Fetal non-stress test | <1% | 8,320 | $84K |
| 73110 | <1% | 4,438 | $83K | |
| G0378 | Hospital observation service, per hour | <1% | 1,246 | $83K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 8,712 | $82K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 31,647 | $82K |
| 99221 | <1% | 2,325 | $81K | |
| 73562 | <1% | 4,522 | $78K | |
| 93308 | <1% | 2,031 | $77K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,719 | $75K |
| 84702 | <1% | 11,902 | $75K | |
| 84703 | <1% | 24,081 | $74K | |
| 86803 | <1% | 3,619 | $73K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 496 | $71K |
| 73564 | <1% | 2,579 | $70K | |
| 0683 | <1% | 473 | $70K | |
| 82607 | <1% | 7,295 | $69K | |
| 73502 | <1% | 2,058 | $68K | |
| 90715 | <1% | 4,737 | $68K | |
| 74018 | <1% | 4,245 | $67K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 397 | $64K |
| 73080 | <1% | 2,742 | $61K | |
| 83789 | <1% | 4,710 | $60K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 2,207 | $60K |
| 93458 | <1% | 107 | $58K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,668 | $58K |
| 87081 | <1% | 10,283 | $58K | |
| 85610 | <1% | 19,893 | $57K | |
| 83050 | <1% | 11,299 | $57K | |
| 72100 | <1% | 2,065 | $56K | |
| 87040 | <1% | 5,867 | $55K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 436 | $55K |
| 73590 | <1% | 3,347 | $52K | |
| 84999 | <1% | 2,535 | $51K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 12,438 | $51K |
| 83721 | <1% | 14,816 | $51K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,660 | $49K |
| 90999 | Dialysis (unlisted procedure) | <1% | 520 | $48K |
| 87430 | <1% | 2,823 | $47K | |
| 97803 | <1% | 1,494 | $47K | |
| 97161 | <1% | 1,474 | $46K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 10,672 | $46K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 175 | $45K |
| 76870 | <1% | 1,441 | $45K | |
| 94729 | <1% | 1,393 | $44K | |
| 86900 | <1% | 18,762 | $43K | |
| 86901 | <1% | 18,766 | $42K | |
| 73090 | <1% | 2,758 | $42K | |
| 94726 | <1% | 1,423 | $41K | |
| Q3014 | Telehealth originating site facility fee | <1% | 2,282 | $41K |
| 94060 | <1% | 1,562 | $41K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 8,824 | $40K |
| 77066 | Tomosynthesis, mammo | <1% | 448 | $40K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,342 | $39K |
| 81003 | <1% | 13,677 | $39K | |
| 86140 | <1% | 8,774 | $38K | |
| 84132 | <1% | 19,010 | $37K | |
| 82948 | <1% | 7,607 | $37K | |
| 76604 | <1% | 1,450 | $36K | |
| 83970 | <1% | 1,126 | $35K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,360 | $34K |
| 84100 | <1% | 10,640 | $33K | |
| 84295 | <1% | 18,619 | $33K | |
| 72170 | <1% | 3,430 | $33K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,899 | $32K |
| 84550 | <1% | 8,015 | $32K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,607 | $32K |
| 85379 | <1% | 6,118 | $32K | |
| 93880 | <1% | 345 | $32K | |
| 85730 | <1% | 8,117 | $31K | |
| 70491 | <1% | 401 | $31K | |
| 87653 | <1% | 1,285 | $31K | |
| 97802 | <1% | 408 | $31K | |
| 76536 | <1% | 630 | $31K | |
| 72050 | <1% | 895 | $31K | |
| 77065 | Tomosynthesis, mammo | <1% | 450 | $30K |
| 72040 | <1% | 1,096 | $30K | |
| 82728 | <1% | 3,162 | $29K | |
| 0710 | <1% | 1,030 | $29K | |
| 47562 | <1% | 182 | $29K | |
| 87186 | <1% | 8,152 | $29K | |
| 82435 | <1% | 17,684 | $29K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,107 | $29K |
| 84480 | <1% | 2,289 | $29K | |
| 86003 | <1% | 316 | $29K | |
| 74019 | <1% | 1,751 | $29K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 4,110 | $28K |
| 82550 | <1% | 5,218 | $27K | |
| 12001 | <1% | 1,641 | $26K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,314 | $25K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 2,026 | $25K |
| 73140 | <1% | 1,811 | $25K | |
| 82746 | <1% | 1,916 | $25K | |
| 83540 | <1% | 4,725 | $24K | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 401 | $24K |
| 87340 | <1% | 1,807 | $23K | |
| 86592 | <1% | 6,651 | $23K | |
| 77336 | <1% | 895 | $22K | |
| 84145 | <1% | 1,784 | $22K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 10,420 | $22K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,301 | $22K |
| 82043 | <1% | 3,119 | $21K | |
| 0300 | <1% | 420 | $21K | |
| 83520 | <1% | 1,821 | $20K | |
| G9793 | Patient is currently on a daily aspirin or other antiplatelet | <1% | 2,054 | $20K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,176 | $20K |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 1,092 | $19K |
| 73552 | <1% | 1,312 | $19K | |
| 85576 | <1% | 415 | $19K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 334 | $19K |
| 85014 | <1% | 18,787 | $18K | |
| 83550 | <1% | 3,486 | $18K | |
| 96367 | <1% | 1,132 | $18K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,584 | $18K |
| 93296 | <1% | 639 | $18K | |
| 70360 | <1% | 1,025 | $18K | |
| 85651 | <1% | 7,640 | $18K | |
| 77412 | <1% | 558 | $17K | |
| 81002 | <1% | 9,458 | $17K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,580 | $17K |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 2,111 | $17K |
| 12011 | <1% | 843 | $16K | |
| 86376 | <1% | 1,315 | $15K | |
| 12002 | <1% | 850 | $15K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,411 | $15K |
| 73060 | <1% | 1,226 | $15K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 177 | $15K |
| 86762 | <1% | 1,083 | $15K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,802 | $14K |
| 97018 | <1% | 299 | $14K | |
| 82010 | <1% | 2,987 | $14K | |
| 87070 | <1% | 2,467 | $14K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 6,380 | $14K |
| 29125 | <1% | 1,121 | $14K | |
| 82140 | <1% | 2,143 | $14K | |
| 84153 | <1% | 820 | $14K | |
| 71250 | <1% | 158 | $14K | |
| 87088 | <1% | 4,799 | $14K | |
| 86635 | <1% | 888 | $14K | |
| 80069 | <1% | 1,556 | $13K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,075 | $13K |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 1,204 | $13K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 411 | $13K |
| 90686 | <1% | 2,277 | $13K | |
| 86038 | <1% | 1,171 | $12K | |
| 84466 | <1% | 1,219 | $12K | |
| 97116 | <1% | 1,589 | $12K | |
| 73221 | <1% | 45 | $11K | |
| 85027 | <1% | 1,988 | $11K | |
| 99401 | <1% | 862 | $11K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,882 | $11K |
| 80164 | <1% | 872 | $11K | |
| 93225 | <1% | 423 | $11K | |
| 85018 | <1% | 10,880 | $11K | |
| 96376 | <1% | 2,582 | $11K | |
| 82248 | <1% | 2,609 | $11K | |
| 82274 | <1% | 708 | $10K | |
| 95816 | <1% | 330 | $10K | |
| 96368 | <1% | 715 | $10K | |
| T2041 | Supports brokerage, self-directed, waiver; per 15 minutes | <1% | 53 | $10K |
| 93000 | <1% | 443 | $10K | |
| 80050 | General health panel | <1% | 752 | $10K |
| 71101 | <1% | 370 | $10K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,770 | $9K |
| 84403 | <1% | 455 | $9K | |
| 82950 | <1% | 1,653 | $9K | |
| 93226 | <1% | 236 | $9K | |
| 82570 | <1% | 1,915 | $9K | |
| 99205 | Prolong outpt/office vis | <1% | 152 | $9K |
| Z9725 | <1% | 197 | $8K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,210 | $8K |
| 29515 | <1% | 679 | $8K | |
| 10060 | <1% | 465 | $8K | |
| 87205 | <1% | 2,837 | $8K | |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 484 | $8K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,661 | $7K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 99 | $7K |
| 72070 | <1% | 364 | $7K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 958 | $7K |
| 87210 | <1% | 2,411 | $7K | |
| 95782 | <1% | 14 | $7K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 807 | $7K |
| 74178 | <1% | 38 | $7K | |
| 0762 | <1% | 988 | $7K | |
| 93356 | <1% | 417 | $6K | |
| 74022 | <1% | 265 | $6K | |
| 36455 | <1% | 334 | $6K | |
| 87505 | <1% | 56 | $6K | |
| 93925 | <1% | 114 | $6K | |
| 86403 | <1% | 583 | $6K | |
| 90837 | Psychotherapy session, about an hour | <1% | 67 | $6K |
| 72158 | <1% | 13 | $6K | |
| 93242 | <1% | 509 | $6K | |
| 87807 | <1% | 871 | $6K | |
| 77334 | <1% | 52 | $6K | |
| 77280 | <1% | 163 | $6K | |
| H1001 | Prenatal care, at-risk enhanced service; antepartum management | <1% | 196 | $6K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,126 | $6K |
| 84436 | <1% | 2,993 | $6K | |
| 73560 | <1% | 438 | $5K | |
| 87220 | <1% | 1,502 | $5K | |
| 73620 | <1% | 209 | $5K | |
| 3074F | <1% | 303 | $5K | |
| 86431 | <1% | 909 | $5K | |
| G8419 | Bmi documented outside normal parameters, no follow-up plan documented, no reason given | <1% | 869 | $5K |
| 76775 | <1% | 166 | $5K | |
| 78451 | <1% | 73 | $5K | |
| 97597 | <1% | 182 | $5K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 634 | $5K |
| 26145 | <1% | 45 | $4K | |
| 93246 | <1% | 305 | $4K | |
| 84146 | <1% | 257 | $4K | |
| 87631 | <1% | 128 | $4K | |
| 87338 | <1% | 445 | $4K | |
| 83001 | <1% | 189 | $4K | |
| 78227 | <1% | 18 | $4K | |
| 76882 | <1% | 192 | $4K | |
| 73120 | <1% | 122 | $4K | |
| 0301 | <1% | 442 | $4K | |
| 85384 | <1% | 651 | $4K | |
| 29530 | <1% | 546 | $4K | |
| 87045 | <1% | 602 | $4K | |
| 90677 | <1% | 12 | $4K | |
| 84479 | <1% | 755 | $4K | |
| 72131 | <1% | 61 | $4K | |
| 90658 | <1% | 217 | $3K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 197 | $3K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 79 | $3K |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 195 | $3K |
| 83615 | <1% | 720 | $3K | |
| 99243 | <1% | 156 | $3K | |
| 3077F | <1% | 124 | $3K | |
| 85045 | <1% | 904 | $3K | |
| 92551 | <1% | 199 | $3K | |
| Z6406 | <1% | 244 | $3K | |
| 83516 | <1% | 268 | $3K | |
| 29240 | <1% | 749 | $3K | |
| 36430 | <1% | 126 | $3K | |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | <1% | 123 | $3K |
| 72072 | <1% | 120 | $3K | |
| 29581 | <1% | 398 | $3K | |
| 84481 | <1% | 381 | $3K | |
| 93297 | <1% | 125 | $3K | |
| 93016 | <1% | 243 | $3K | |
| 84155 | <1% | 921 | $3K | |
| 84520 | <1% | 530 | $3K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,165 | $3K |
| 82784 | <1% | 314 | $3K | |
| 77080 | <1% | 92 | $2K | |
| 3079F | <1% | 239 | $2K | |
| 51798 | <1% | 149 | $2K | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | <1% | 408 | $2K |
| 82553 | <1% | 160 | $2K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 388 | $2K |
| 67042 | <1% | 13 | $2K | |
| 87581 | <1% | 129 | $2K | |
| 73000 | <1% | 92 | $2K | |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 247 | $2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 239 | $2K |
| 87046 | <1% | 570 | $2K | |
| 87486 | <1% | 129 | $2K | |
| 0510 | <1% | 1,572 | $2K | |
| 82565 | <1% | 441 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 384 | $2K |
| 76000 | <1% | 82 | $2K | |
| 71020 | <1% | 338 | $2K | |
| 29130 | <1% | 401 | $2K | |
| 99223 | Prolong inpt eval add15 m | <1% | 49 | $2K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 213 | $2K |
| 87899 | <1% | 212 | $2K | |
| 82310 | <1% | 385 | $2K | |
| 86677 | <1% | 160 | $2K | |
| 85390 | <1% | 413 | $2K | |
| 86787 | <1% | 154 | $2K | |
| 84156 | <1% | 809 | $2K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,321 | $2K |
| 86308 | <1% | 327 | $2K | |
| 97166 | <1% | 312 | $2K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 13 | $2K |
| 69209 | <1% | 246 | $2K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 203 | $2K |
| 86703 | <1% | 117 | $2K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 12 | $2K |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 187 | $2K |
| 99218 | <1% | 288 | $1K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 58 | $1K |
| 84157 | <1% | 690 | $1K | |
| 0324 | <1% | 505 | $1K | |
| J3372 | Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mg | <1% | 99 | $1K |
| J3260 | Injection, tobramycin sulfate, up to 80 mg | <1% | 81 | $1K |
| 97016 | <1% | 470 | $1K | |
| 74174 | <1% | 12 | $1K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 383 | $1K |
| 73070 | <1% | 124 | $1K | |
| 82272 | <1% | 166 | $1K | |
| 86800 | <1% | 137 | $1K | |
| 92610 | <1% | 29 | $1K | |
| 51702 | <1% | 89 | $1K | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 97 | $1K |
| 85347 | <1% | 430 | $1K | |
| 73600 | <1% | 46 | $1K | |
| 82530 | <1% | 81 | $1K | |
| 71100 | <1% | 57 | $1K | |
| 74220 | <1% | 59 | $1K | |
| 90732 | <1% | 13 | $1K | |
| 84402 | <1% | 95 | $1K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 29 | $1K |
| 82610 | <1% | 117 | $1K | |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | <1% | 15 | $1K |
| 90746 | <1% | 13 | $1K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 23 | $1K |
| 82810 | <1% | 164 | $1K | |
| 80081 | <1% | 12 | $1K | |
| 0370 | <1% | 357 | $994.76 | |
| 87449 | <1% | 104 | $991.79 | |
| 95819 | <1% | 38 | $981.37 | |
| 76376 | <1% | 303 | $979.85 | |
| 82378 | <1% | 122 | $964.40 | |
| 84460 | <1% | 218 | $914.81 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 131 | $903.14 |
| 49083 | <1% | 15 | $887.32 | |
| 73660 | <1% | 91 | $871.16 | |
| 84134 | <1% | 84 | $870.17 | |
| 93350 | <1% | 18 | $860.09 | |
| 84450 | <1% | 206 | $848.48 | |
| 29105 | <1% | 84 | $834.58 | |
| 86769 | <1% | 26 | $820.13 | |
| 85008 | <1% | 997 | $819.12 | |
| 83002 | <1% | 36 | $791.35 | |
| 64721 | <1% | 12 | $759.00 | |
| 87184 | <1% | 227 | $730.46 | |
| 76999 | <1% | 25 | $704.74 | |
| 86920 | <1% | 21 | $691.53 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 104 | $689.00 |
| 51701 | <1% | 174 | $684.14 | |
| 80178 | <1% | 105 | $674.69 | |
| 85007 | <1% | 885 | $641.79 | |
| 82785 | <1% | 40 | $615.97 | |
| 90688 | <1% | 74 | $576.38 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 58 | $536.35 |
| 73521 | <1% | 25 | $534.39 | |
| 82977 | <1% | 72 | $531.92 | |
| 3075F | <1% | 28 | $531.45 | |
| 82105 | <1% | 14 | $520.69 | |
| 70487 | <1% | 13 | $504.28 | |
| 82040 | <1% | 148 | $502.04 | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 45 | $492.12 |
| 72220 | <1% | 27 | $477.82 | |
| 90675 | <1% | 24 | $477.16 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 128 | $472.87 |
| 29260 | <1% | 281 | $451.30 | |
| 82945 | <1% | 176 | $446.37 | |
| Z7500 | <1% | 13 | $443.30 | |
| 82731 | <1% | 14 | $440.50 | |
| 80329 | <1% | 93 | $439.86 | |
| 92558 | <1% | 15 | $435.56 | |
| 84075 | <1% | 119 | $435.52 | |
| 84270 | <1% | 27 | $435.22 | |
| 82575 | <1% | 52 | $399.22 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,116 | $387.39 |
| 82652 | <1% | 40 | $378.98 | |
| 83037 | <1% | 287 | $375.47 | |
| 86171 | <1% | 30 | $370.24 | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 16 | $366.94 |
| 82247 | <1% | 72 | $365.44 | |
| 86331 | <1% | 30 | $346.25 | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 19 | $340.20 |
| Z7610 | <1% | 26 | $321.87 | |
| 73100 | <1% | 12 | $320.99 | |
| Z6404 | <1% | 12 | $289.56 | |
| 81050 | <1% | 149 | $252.26 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 150 | $241.50 |
| 93321 | <1% | 13 | $233.06 | |
| 83993 | <1% | 12 | $228.44 | |
| 71010 | <1% | 88 | $224.77 | |
| 86200 | <1% | 34 | $219.31 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 16 | $194.38 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 189 | $189.86 |
| 86706 | <1% | 12 | $169.20 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 53 | $167.54 |
| 94760 | <1% | 19 | $138.30 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 44 | $133.38 |
| 84165 | <1% | 25 | $131.04 | |
| 0305 | <1% | 319 | $129.71 | |
| 3080F | <1% | 12 | $115.48 | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 16 | $113.65 |
| 86256 | <1% | 13 | $103.90 | |
| 29540 | <1% | 131 | $97.44 | |
| 0320 | <1% | 32 | $96.67 | |
| 0730 | <1% | 12 | $89.51 | |
| 87075 | <1% | 16 | $88.38 | |
| 82374 | <1% | 68 | $79.33 | |
| 99000 | <1% | 143 | $73.28 | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 33 | $72.68 |
| 99173 | <1% | 152 | $64.64 | |
| 90651 | <1% | 13 | $61.65 | |
| 83930 | <1% | 12 | $57.92 | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 16 | $54.84 |
| 87077 | <1% | 27 | $53.66 | |
| 86880 | <1% | 13 | $47.87 | |
| 93018 | <1% | 14 | $45.15 | |
| 0636 | <1% | 38 | $39.60 | |
| 86300 | <1% | 13 | $35.76 | |
| G9724 | Patients who had documentation of use of anticoagulant medications overlapping the measurement year | <1% | 31 | $24.04 |
| 36000 | <1% | 16 | $21.80 | |
| G8483 | Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) | <1% | 47 | $17.71 |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 13 | $16.12 |
| G8482 | Influenza immunization administered or previously received | <1% | 309 | $14.13 |
| A4657 | Syringe, with or without needle, each | <1% | 580 | $0.03 |
| S9088 | Services provided in an urgent care center (list in addition to code for service) | 0% | 80 | $0.00 |
| 97014 | 0% | 92 | $0.00 | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 0% | 18 | $0.00 |
| G8986 | Carrying, moving & handling objects functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 13 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 15 | $0.00 |
| A4649 | Surgical supply; miscellaneous | 0% | 206 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 60 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 142 | $0.00 |
| 0940 | 0% | 40 | $0.00 | |
| 0370R | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTUPPER, MALINDA (SRVP/CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Kaweah Delta Health Care District | Exeter, CA | $68.84M |
| Kaweah Delta Health Care District | Visalia, CA | $15.37M |
| Kaweah Delta Health Care District | Lindsay, CA | $12.83M |
| Kaweah Delta Health Care District | Dinuba, CA | $10.04M |
| Kaweah Delta Health Care District | Woodlake, CA | $8.03M |
| Kaweah Delta Health Care District | Visalia, CA | $5.60M |
| Kaweah Delta Health Care District | Tulare, CA | $4.95M |
| Kaweah Delta Health Care District | Visalia, CA | $2.71M |
| Kaweah Delta Health Care District | Visalia, CA | $2.30M |
| Kaweah Delta Health Care District | Visalia, CA | $1.01M |
| Kaweah Delta Health Care District | Visalia, CA | $809K |
| Kaweah Delta Health Care District | Visalia, CA | $587K |
| Kaweah Delta Health Care District | Visalia, CA | $388K |
| Kaweah Delta Health Care INC | Visalia, CA | $353K |
| Kaweah Delta Health Care District | Visalia, CA | $70K |
| Kaweah Delta Health Care District | Tulare, CA | $54K |
| Kaweah Delta Health Care District | Visalia, CA | $10K |
| Kaweah Delta Health Care District | Visalia, CA | $3K |
| Kaweah Delta Health Care District | Visalia, CA | $3K |
| Kaweah Delta Health Care District | Visalia, CA | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.